The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

PROVEN EFFICACY IN PALMOPLANTAR PSORIASIS1

Significantly more patients clear or almost clear vs placebo1,a,b

Created with Highcharts 8.0.4Week 16OTEZLA 30 mg BID (n = 92)Placebo (n = 52)0102030405060708090100
Patients Achieving PPPGA Score
of 0 or 1 (%)
27%
48%
PSO-charts-table-PALM
Woman and man standing beside a dining table

aPost-hoc analysis of pooled patient data from the phase 3 ESTEEM 1 and 2 studies and the phase 2 PSOR-005 study. Among patients with moderate to severe palmoplantar psoriasis at baseline (PPPGA score ≥3; 10.1% [n = 144/1,431]).

bP = 0.021.

OTEZLA cleared or almost cleared psoriasis on the palms and soles1

See the OTEZLA difference

Real patients, real pictures*

Actual patient with palmoplantar psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Baseline

Actual patient with palmoplantar psoriasis after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.

Week 16 PASI-70 result

Individual results may vary.

*Photos taken from the ESTEEM clinical trial program, which evaluated OTEZLA 30 mg BID in patients with active plaque psoriasis.

BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PPPGA, Palmoplantar Psoriasis Physician Global Assessment.

Reference:

  1. Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016;75(1):99-105.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.